<DOC>
	<DOCNO>NCT02959619</DOCNO>
	<brief_summary>This study aim determine maximum tolerate dose ensartinib , oral ALK inhibitor Chinese patient ALK-positive non-small cell lung cancer</brief_summary>
	<brief_title>Ensartinib Non-small Cell Lung Cancer Patients With Positive ALK</brief_title>
	<detailed_description>The initial purpose study determine large amount ensartinib safely give human . An expansion phase conduct assess preliminary anti-tumor activity ALK-positive non-small cell lung cancer recommend Phase 2 dose establish .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis advance solid tumor malignancy For expanded cohort portion study , patient must NSCLC ALK genomic alteration positive FISH IHC Eastern Cooperative Group ECOG ) Performance Status score 0 1 Adequate organ system function Male patient willing use adequate contraceptive measure ; female patient childbearing potential , female patient childbearing potential agree use adequate contraceptive measure Measurable disease per RECIST Willingness ability comply trial followup procedure Written inform consent require indicate patient aware investigational nature study Current use anticancer therapy . Use investigational drug within 14 day 5 halflives ( whichever short ) prior first dose ensartinib Any major surgery , radiotherapy , immunotherapy within last 21 day . Chemotherapy regimens delay toxicity within last 4 week . Chemotherapy regimens give continuously weekly basis limit potential delayed toxicity within last 2 week . Prior stem cell transplant Patients know allergy delay hypersensitivity reaction drug chemically relate ensartinib active ingredient ensartinib Prior use ALK TKIs exception crizotinib Primary CNS tumor meningeal metastasis Pregnant breastfeed female Presence active gastrointestinal ( GI ) disease condition interfere significantly absorption , distribution , metabolism , excretion ensartinib Clinically significant cardiovascular disease . Psychological , familial , sociological , geographical condition permit compliance protocol Concurrent condition evaluate investigator would jeopardize compliance protocol would impart excessive risk associate study participation would make inappropriate patient enrol Inability unwillingness comply study and/or followup procedure outline protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>